Author

P. Sahasrabudhe

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:multiome· 1 Organism:non-human primate· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. Muik· 2 shared K. Swanson· 2 shared Y. Che· 2 shared A. B. Vogel· 1 shared A. Gueler· 1 shared A. Heinen· 1 shared A. Plaschke· 1 shared A. S. Anderson· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Muik

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine

K. Modjarrad, Y. Che, W. Chen, H. Wu, C. I. Cadima, A. Muik, M. S. Maddur, K. R. Tompkins, L. T. Martinez, H. Cai, M. Hong, S. Mensah, B. Cumbia, L. Falcao, J. S. Chang, , K. Swanson

The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.

bioRxiv · Nov 17, 2023Immunology

ABC-transporter CFTR folds with high fidelity through a modular, stepwise pathway

J. Im, T. Hillenaar, H. Y. Yeoh, P. Sahasrabudhe, M. Mijnders, M. van Willigen, P. van der Sluijs, I. Braakman

This study reveals the stepwise folding pathway of CFTR, showing two distinct stages of domain folding and assembly, with implications for understanding protein misfolding diseases.

bioRxiv · Jul 20, 2022Biochemistry

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates

A. Vogel, I. Kanevsky, Y. Che, K. Swanson, A. Muik, M. Vormehr, L. Kranz, K. Walzer, S. Hein, A. Gueler, J. Loschko, M. Maddur, K. Tompkins, J. Cole, B. G. Lui, , Ciolin

This paper reports on a prefusion SARS-CoV-2 spike RNA vaccine that induces strong immune responses and prevents lung infection in non-human primates.

bioRxiv · Sep 8, 2020 · PreprintImmunology